We are a specialty pharmaceutical company that applies proprietary technologies to develop new products and improved formulations of existing drugs that target current unmet and underserved medical needs primarily in the acute care pain management market. We are developing and have begun to market simple and user-friendly products, involving new modes and routes of delivery for drugs optimized for relieving acute moderate-to-severe pain. In doing so, we intend to offer novel proprietary products that in some cases can be administered in a less invasive, more convenient manner and generally should offer either improved safety or efficacy, or both, as compared to formulations that are currently marketed by other companies. In addition, the product choices currently available for the treatment of acute moderate-to-severe pain are limited in the doses that may be given due to side effects including cardiovascular depression, tolerance and addiction, respiratory depression, constipation, sedation and general diminution of quality of life. Our product candidates - Dyloject™ (injectable diclofenac), Ereska™ (intranasal ketamine) and Rylomine™ (intranasal morphine) - are focused on treating a variety of pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain such as orthopedic injury pain, procedural pain and burn pain. We believe that our products, assuming regulatory approvals, will offer patients and the medical community significant benefits and alternatives to the prescription pain medications available to pain sufferers today.
Company profile
Ticker
JAV
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Intrac Inc
SEC CIK
Corporate docs
IRS number
880471759
Latest filings (excl ownership)
15-12B
Securities registration termination
16 Jul 10
25-NSE
Exchange delisting
6 Jul 10
EFFECT
Notice of effectiveness
6 Jul 10
EFFECT
Notice of effectiveness
6 Jul 10
EFFECT
Notice of effectiveness
6 Jul 10
8-K
Completion of Acquisition or Disposition of Assets
2 Jul 10
POS AM
Prospectus update (post-effective amendment)
2 Jul 10
POS AM
Prospectus update (post-effective amendment)
2 Jul 10
POS AM
Prospectus update (post-effective amendment)
2 Jul 10
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 10